Solid Bio FDA IND Clearance for First-In-Industry Gene Therapy to Treat Friedreich’s Ataxia

 - SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich’s ataxia -

- Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and heart to potentially address the most significant symptoms of the disease -

- Phase 1b clinical trial initiation expected in 2H 2025 -

- Company to hold a conference call tomorrow, January 8, 2025, at 8:30 AM ET -

The Company will host a conference call tomorrow, January 8, 2025, at 8:30 AM ET to discuss the IND clearance for SGT-212 as well as other corporate updates. A live and archived webcast of the call will be available on Solid’s website at www.solidbio.com under the “News & Events” tab in the Investor Relations section, or by clicking here.

Participants may also access the live call by dialing 877-409-2291 (toll-free) or 201-389-0925 (international).

https://www.globenewswire.com/news-release/2025/01/07/3005854/0/en/Solid-Biosciences-Announces-FDA-IND-Clearance-for-First-In-Industry-Dual-Route-of-Administration-Gene-Therapy-to-Treat-Both-Neurologic-and-Cardiac-Manifestations-of-Friedreich-s-At.html